Just reported
From Becton, Dickinson's results release of 5 novembre 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
5,27B USD
-36% y/y
+5,8% q/q
Guided
—
No guide given
Actual
2,54 USD
+48% y/y
+85% q/q
Guided
—
No guide given
EPS, adjusted: 2,52 USD
Actual
1,03B USD
-12% y/y
+56% q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Costruito dai documenti depositati da Becton, Dickinson And Company presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
The themes Becton, Dickinson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
BDX · NYSE · Healthcare · Medical Instruments and Supplies
215,74 USD+0,6%chiusura 12 nov
The latest quarter (ended 30 settembre 2026) is from Becton, Dickinson’s earnings press release of 5 novembre 2026. It will be replaced by the official annual report (10-K) once Becton, Dickinson files it.
Grade D
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 41 dello storico dei voti di Becton, Dickinson And Company. Gli altri 39 risalgono fino a novembre 2016.